Haemonetics Corp
NYSE:HAE

Watchlist Manager
Haemonetics Corp Logo
Haemonetics Corp
NYSE:HAE
Watchlist
Price: 85.55 USD 0.14% Market Closed
Market Cap: 4.3B USD
Have any thoughts about
Haemonetics Corp?
Write Note

Intrinsic Value

The intrinsic value of one HAE stock under the Base Case scenario is 99.89 USD. Compared to the current market price of 85.55 USD, Haemonetics Corp is Undervalued by 14%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HAE Intrinsic Value
99.89 USD
Undervaluation 14%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Haemonetics Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for HAE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about HAE?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Haemonetics Corp

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Haemonetics Corp

Provide an overview of the primary business activities
of Haemonetics Corp.

What unique competitive advantages
does Haemonetics Corp hold over its rivals?

What risks and challenges
does Haemonetics Corp face in the near future?

Has there been any significant insider trading activity
in Haemonetics Corp recently?

Summarize the latest earnings call
of Haemonetics Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Haemonetics Corp.

Provide P/S
for Haemonetics Corp.

Provide P/E
for Haemonetics Corp.

Provide P/OCF
for Haemonetics Corp.

Provide P/FCFE
for Haemonetics Corp.

Provide P/B
for Haemonetics Corp.

Provide EV/S
for Haemonetics Corp.

Provide EV/GP
for Haemonetics Corp.

Provide EV/EBITDA
for Haemonetics Corp.

Provide EV/EBIT
for Haemonetics Corp.

Provide EV/OCF
for Haemonetics Corp.

Provide EV/FCFF
for Haemonetics Corp.

Provide EV/IC
for Haemonetics Corp.

Show me price targets
for Haemonetics Corp made by professional analysts.

What are the Revenue projections
for Haemonetics Corp?

How accurate were the past Revenue estimates
for Haemonetics Corp?

What are the Net Income projections
for Haemonetics Corp?

How accurate were the past Net Income estimates
for Haemonetics Corp?

What are the EPS projections
for Haemonetics Corp?

How accurate were the past EPS estimates
for Haemonetics Corp?

What are the EBIT projections
for Haemonetics Corp?

How accurate were the past EBIT estimates
for Haemonetics Corp?

Compare the revenue forecasts
for Haemonetics Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Haemonetics Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Haemonetics Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Haemonetics Corp compared to its peers.

Compare the P/E ratios
of Haemonetics Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Haemonetics Corp with its peers.

Analyze the financial leverage
of Haemonetics Corp compared to its main competitors.

Show all profitability ratios
for Haemonetics Corp.

Provide ROE
for Haemonetics Corp.

Provide ROA
for Haemonetics Corp.

Provide ROIC
for Haemonetics Corp.

Provide ROCE
for Haemonetics Corp.

Provide Gross Margin
for Haemonetics Corp.

Provide Operating Margin
for Haemonetics Corp.

Provide Net Margin
for Haemonetics Corp.

Provide FCF Margin
for Haemonetics Corp.

Show all solvency ratios
for Haemonetics Corp.

Provide D/E Ratio
for Haemonetics Corp.

Provide D/A Ratio
for Haemonetics Corp.

Provide Interest Coverage Ratio
for Haemonetics Corp.

Provide Altman Z-Score Ratio
for Haemonetics Corp.

Provide Quick Ratio
for Haemonetics Corp.

Provide Current Ratio
for Haemonetics Corp.

Provide Cash Ratio
for Haemonetics Corp.

What is the historical Revenue growth
over the last 5 years for Haemonetics Corp?

What is the historical Net Income growth
over the last 5 years for Haemonetics Corp?

What is the current Free Cash Flow
of Haemonetics Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Haemonetics Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Haemonetics Corp

Current Assets 955.9m
Cash & Short-Term Investments 299.3m
Receivables 213.5m
Other Current Assets 443.1m
Non-Current Assets 1.6B
PP&E 300.5m
Intangibles 1.1B
Other Non-Current Assets 164.8m
Current Liabilities 273.9m
Accounts Payable 69.2m
Accrued Liabilities 49.3m
Other Current Liabilities 155.4m
Non-Current Liabilities 1.4B
Long-Term Debt 1.2B
Other Non-Current Liabilities 152.9m
Efficiency

Earnings Waterfall
Haemonetics Corp

Revenue
1.4B USD
Cost of Revenue
-625.9m USD
Gross Profit
735.3m USD
Operating Expenses
-520.2m USD
Operating Income
215m USD
Other Expenses
-91.2m USD
Net Income
123.8m USD

Free Cash Flow Analysis
Haemonetics Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Haemonetics achieved a second quarter revenue of $346 million, representing a 9% increase year-over-year. Adjusted earnings per share rose 13% to $1.12. The company raised its organic revenue growth guidance from 1-3% to 1-4% for the fiscal year 2025. The adjusted operating margin guidance remained between 23-24%, amid expanding hospital business and product uptake. Notably, plasma revenue is projected to decline 3-6%, influenced by a $100 million contribution from CSL. Conversely, Haemonetics anticipates a strong 31% growth in hospital revenue, driven by innovative products like the VASCADE MVP XL. The firm maintains a focus on shareholder returns, with ongoing stock buybacks.

What is Earnings Call?
Fundamental Scores

HAE Profitability Score
Profitability Due Diligence

Haemonetics Corp's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
ROE is Increasing
58/100
Profitability
Score

Haemonetics Corp's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

HAE Solvency Score
Solvency Due Diligence

Haemonetics Corp's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Average Altman Z-Score
Average D/E
53/100
Solvency
Score

Haemonetics Corp's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HAE Price Targets Summary
Haemonetics Corp

Wall Street analysts forecast HAE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HAE is 113.02 USD with a low forecast of 85.85 USD and a high forecast of 131.25 USD.

Lowest
Price Target
85.85 USD
0% Upside
Average
Price Target
113.02 USD
32% Upside
Highest
Price Target
131.25 USD
53% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for HAE?

Click here to dive deeper.

Dividends

Haemonetics Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for HAE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

HAE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Haemonetics Corp Logo
Haemonetics Corp

Country

United States of America

Industry

Health Care

Market Cap

4.3B USD

Dividend Yield

0%

Description

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 2,708 full-time employees. The firm provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.

Contact

MASSACHUSETTS
Boston
125 Summer Street
+17818487100.0
www.haemonetics.com

IPO

1979-10-17

Employees

2 708

Officers

CEO, President & Director
Mr. Christopher A. Simon
CFO, Executive VP & Financial Officer
Mr. James C. D'Arecca CPA
Executive VP & CTO
Ms. Anila Lingamneni
Executive VP, General Counsel & Secretary
Ms. Michelle L. Basil
Executive Vice President of Global Manufacturing & Supply Chain
Mr. Josep Lluis Llorens
VP, Chief Accounting Officer & Principal Accounting Officer
Ms. Farris Maryanne Maunsell
Show More
Senior Director of Investor Relations
Ms. Olga Guyette
Senior Vice President of Strategy & Corporate Development
Mr. Rajeev Varma
Senior VP & Chief Human Resources Officer
Ms. Laurie A. Miller
Senior VP & Chief Medical Officer
Dr. Jan Hartmann M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one HAE stock?

The intrinsic value of one HAE stock under the Base Case scenario is 99.89 USD.

Is HAE stock undervalued or overvalued?

Compared to the current market price of 85.55 USD, Haemonetics Corp is Undervalued by 14%.

Back to Top